Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) in Patients with Solid Tumors, including Pancreatic Cancer
The purpose of this phase I/IIB trial is to evaluate the safety and tolerability of T-cell receptor gene-engineered T cells (TCR-T) in combination with pembrolizumab and CDX-1140 in patients with solid tumors, including pancreatic cancer.
Study ID: 2020000584
Trial Phase: Phase I
Trial Sponsor: Providence Portland Medical Center
Therapies Used in This Trial: CDX-1140, Pembrolizumab, TCR-transduced T cells